Page 557 - Read Online

Puckett et al. J Cancer Metastasis Treat 2020;6:44 Journal of Cancer
DOI: 10.20517/2394-4722.2020.98 Metastasis and Treatment

Review Open Access

Is there a role for resection of oligometastatic
disease in pancreatic ductal adenocarcinoma?

Yana Puckett , Mariam F. Eskander , Christopher T. Aquina , Timothy M. Pawlik 2
1
2
2
1 Department of Surgery, West Virginia University School of Medicine, Charleston, WV 25340, USA.
2 Department of Surgical Oncology, The Ohio State University, Columbus, OH 43210, USA.
Correspondence to: Prof. Timothy M. Pawlik, Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer
Research, The Ohio State University, Wexner Medical Center, 395 W. 12th Ave, Suite 670, Columbus, OH 43210, USA.
E-mail: tim.pawlik@osumc.edu
How to cite this article: Puckett Y, Eskander MF, Aquina CT, Pawlik TM. Is there a role for resection of oligometastatic disease in
setting of pancreatic ductal adenocarcinoma? J Cancer Metastasis Treat 2020;6:44.
http://dx.doi.org/10.20517/2394-4722.2020.98

Received: 11 Aug 2020 First Decision: 15 Sep 2020 Revised: 30 Sep 2020 Accepted: 14 Oct 2020 Published: 11 Nov 2020
Academic Editor: Lucio Miele Copy Editor: Cai-Hong Wang Production Editor: Jing Yu

Abstract
It is estimated that approximately 80%-90% of pancreatic ductal adenocarcinoma (PDAC) will present with
unresectable disease with about half of patients presenting with distant metastases. The prognosis of these
patients is generally poor with an average life expectancy of approximately 6 months and a median 5-year survival
of 1%. The current standard of care for metastatic PDAC patients is palliative chemotherapy, as surgery in this
setting does not lead to better survival. More recently, some centers have utilized very specific patient selection
to perform resection of oligometastatic disease with reported improvement in survival - with many centers using
response to systemic therapy as a sign of favorable biology. We performed a literature review investigating the
role of surgical resection of oligometastatic disease of the lung and liver in PDAC.

Keywords: Pancreatic cancer, pancreatic ductal adenocarcinoma, liver metastasis, oligometastatic disease, M1,
surgery, metastasectomy

INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 3% of all cancers and about 8% of
[1]
all cancer deaths in the United States . Despite improvements in surgical technique and chemotherapy
regimens, the 5-year relative survival for pancreatic cancer has only increased from 3% to 9% over the last

© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.jcmtjournal.com